These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 1714865)
1. [Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations]. Sutor AH Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):595-9. PubMed ID: 1714865 [TBL] [Abstract][Full Text] [Related]
2. [Hemostasis disorders after transfusions]. Weissbach G; Domula M; Lenk H Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(3):345-66. PubMed ID: 6169596 [TBL] [Abstract][Full Text] [Related]
3. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management. Mahasandana C; Patharathienskul D; Suvatte V Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549 [TBL] [Abstract][Full Text] [Related]
4. Hemophilia. Strategies for the treatment of inhibitor patients. Ingerslev J Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863 [TBL] [Abstract][Full Text] [Related]
5. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease. Brinkhous KM Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773 [TBL] [Abstract][Full Text] [Related]
6. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor]. Klukowska A; Zieleniewska B Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036 [TBL] [Abstract][Full Text] [Related]
7. [The factor VIII complex: hemophilia A and von Willebrand disease]. Tobelem G; Rothschild C Sem Hop; 1982 Sep; 58(35):2032-6. PubMed ID: 6293093 [TBL] [Abstract][Full Text] [Related]
8. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII]. Hrubisková K Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(4):672-82. PubMed ID: 6162735 [TBL] [Abstract][Full Text] [Related]
9. Hemophiliacs with inhibitors: therapeutic options. Roberts HR N Engl J Med; 1981 Sep; 305(13):757-8. PubMed ID: 6790992 [No Abstract] [Full Text] [Related]
10. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients]. Briët E; Mauser-Bunschoten EP Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158 [TBL] [Abstract][Full Text] [Related]
11. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Buchanan GR; Kevy SV Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319 [TBL] [Abstract][Full Text] [Related]
12. [Current clinical aspects in hemophilia treatment]. Meili EO Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219 [TBL] [Abstract][Full Text] [Related]
13. Recent advances in hemophilia. Tann G Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):218-28. PubMed ID: 524146 [TBL] [Abstract][Full Text] [Related]
14. Transfusion support for haemophiliacs. Allain JP Clin Haematol; 1984 Feb; 13(1):99-117. PubMed ID: 6426835 [No Abstract] [Full Text] [Related]
15. Substitution treatment of hemophilia a and b. Duckert F Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162 [TBL] [Abstract][Full Text] [Related]
16. Treatment of the bleeding tendency in uremia with cryoprecipitate. Janson PA; Jubelirer SJ; Weinstein MJ; Deykin D N Engl J Med; 1980 Dec; 303(23):1318-22. PubMed ID: 6776402 [TBL] [Abstract][Full Text] [Related]
17. Increased fibrinopeptide A after prothrombin complex concentrates. Viganó S; Cattaneo M; Gervasoni W; Mannucci PM Thromb Haemost; 1980 Oct; 44(2):72-5. PubMed ID: 6779400 [TBL] [Abstract][Full Text] [Related]